Related Experiment Video
Updated: Aug 1, 2026

DNBS/TNBS Colitis Models: Providing Insights Into Inflammatory Bowel Disease and Effects of Dietary Fat
Published on: February 27, 2014
Rectal Delivery of a DNAzyme That Specifically Blocks the Transcription Factor GATA3 and Reduces Colitis in Mice
Vanessa Popp1, Katharina Gerlach1, Stefanie Mott1
1Department of Medicine, University of Erlangen-Nürnberg, Kussmaul Research Campus, Erlangen, Germany.
Background & Aims:
GATA3 is a transcription factor that regulates T-cell production of cytokines. We investigated the role of GATA3 in development of colitis in mice.
Methods:
We performed quantitative polymerase chain reaction and immunofluorescence analyses of colon tissues from patients with Crohn's disease (n = 61) or ulcerative colitis (UC, n = 74) or from patients without inflammatory bowel diseases (n = 22), to measure levels of GATA3. Colitis was induced by administration of oxazolone or 2,4,6-trinitrobenzenesulfonic acid to control mice, mice with T-cell-specific deletion of GATA3, and mice with deletion of tumor necrosis factor receptor (TNFR) 1 and TNFR2 (TNFR double knockouts); some mice were given a GATA3-specific DNAzyme (hgd40) or a control DNAzyme via intrarectal administration, or systemic injections of an antibody to TNF before or during sensitization and challenge phase of colitis induction. Colon tissues were collected and immunofluorescence and histochemical analyses were performed. Lamina propria mononuclear cells and T cells were isolated and analyzed by flow cytometry or cytokine assays. Colonic distribution of labeled DNAzyme and inflammation were monitored by in vivo imaging (endoscopy) of mice.
Results:
Levels of GATA3 messenger RNA were higher in colon tissues from patients with UC, but not ileal Crohn's disease, than control tissues; levels of GATA3 correlated with levels of inflammatory cytokines (interleukin [IL] 9, IL17A, IL6, IL5, IL4, IL13, and TNF). We observed increased expression of GATA3 by lamina propria T cells from mice with colitis compared with controls. Mice with T-cell-specific deletion of GATA3 did not develop colitis and their colonic tissues did not produce inflammatory cytokines (IL6, IL9, or IL13). The DNAzyme hgd40 inhibited expression of GATA3 messenger RNA by unstimulated and stimulated T cells, and distributed throughout the inflamed colons of mice with colitis. Colon tissues from mice given hgd40 had reduced expression of GATA3 messenger RNA, compared with mice given a control DNAzyme. Mice given hgd40 did not develop colitis after administration of oxazolone or 2,4,6-trinitrobenzenesulfonic acid; lamina propria cells from these mice expressed lower levels of IL6, IL9, and IL13 than cells from mice given the control DNAzyme. Mini-endoscopic images revealed that hgd40 and anti-TNF reduced colon inflammation over 3 days; hgd40 reduced colitis in TNFR double-knockout mice.
Conclusions:
Levels of GATA3 are increased in patients with UC and correlate with production of inflammatory cytokines in mice and humans. A DNAzyme that prevents expression of GATA3 reduces colitis in mice, independently of TNF, and reduces levels of cytokines in the colon. This DNAzyme might be developed for treatment of patients with UC.
Insights
GATA3 is elevated in ulcerative colitis (UC) and drives inflammatory cytokine production. A GATA3-specific DNAzyme (hgd40) effectively reduced colitis in mice, suggesting potential for UC treatment.
Area of Science:
- Immunology
- Gastroenterology
- Molecular Biology
Background:
- GATA3 is a key transcription factor regulating T-cell cytokine production.
- Investigated the role of GATA3 in the development of colitis.
- GATA3 expression is linked to inflammatory responses in T cells.
Purpose of the Study:
- To determine the role of GATA3 in colitis development.
- To assess the therapeutic potential of targeting GATA3 in ulcerative colitis (UC).
- To evaluate a GATA3-specific DNAzyme (hgd40) for colitis treatment.
Main Methods:
- Quantitative PCR and immunofluorescence on human and mouse colon tissues.
- Induction of colitis in mice using oxazolone or TNBS, with genetic modifications (GATA3 deletion, TNFR knockout).
- Administration of GATA3-specific DNAzyme (hgd40) or control DNAzyme, anti-TNF antibody, and in vivo imaging.
Main Results:
- GATA3 mRNA levels were higher in UC patients' colon tissues and correlated with inflammatory cytokines.
- T-cell-specific GATA3 deletion prevented colitis development in mice.
- The DNAzyme hgd40 inhibited GATA3 expression, reduced colitis, and decreased inflammatory cytokine levels in mice.
Conclusions:
- GATA3 levels are elevated in UC and correlate with inflammatory cytokine production.
- A GATA3-targeting DNAzyme (hgd40) effectively reduced colitis in mouse models, independent of TNF signaling.
- The GATA3-specific DNAzyme hgd40 shows promise as a novel therapeutic agent for ulcerative colitis.
More Related Videos
09:31Effects of Taste Signaling Protein Abolishment on Gut Inflammation in an Inflammatory Bowel Disease Mouse Model
Published on: November 9, 2018
09:08Investigating Target Gene Function in a CD40 Agonistic Antibody-induced Colitis Model using CRISPR/Cas9-based Technologies
Published on: June 2, 2021